Drug Trial Radar · NCT05353257
A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Jan 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
511
Actual
Start
May 17, 2022
Primary completion
Jun 30, 2026
Study completion May 30, 2028
Sponsor
- Lead sponsor
- Shanghai Henlius BiotechIndustry
- Sponsor type
- Industry
- First posted
- Apr 29, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a randomized, double-blind, multicenter, phase III clinical study to compare the clinical efficacy and safety of Serplulimab + chemotherapy+ concurrent radiotherapy vs chemotherapy+ concurrent radiotherapy in subjects with Limited-Stage Small Cell Lung Cancer.
Conditions
- Limited-Stage Small Cell Lung Cancer
Interventions
HLX10Drug
Serplulimab is an innovative monoclonal antibody targeting PD-1,developed by Shanghai Henlius Biotech, Inc. 300mg Q3W
carboplatin/cisplatin-etoposideDrug
Etoposide: 100 mg/m2, IV, on Days 1, 2, and 3 of each cycle. Carboplatin: AUC = 5, IV, on Day 1 of each cycle up to a dose of 750 mg. investigator's choice. Cisplatin: 75mg/m2, IV, on Days 1 of each cycle. investigator's choice.
Thoracic radiotherapyRadiation
Standard Thoracic Radiotherapy
PlaceboDrug
Placebo Q3W
Prophylactic Cranial Irradiation (PCI)Radiation
PCI will be strongly recommended for participants who achieve CR or PR after completion of chemoradiation treatment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS)Time frame: up to approximately 24months
- Overall survival (OS)Time frame: up to 36 months
Locations
129 sites in 11 countries. Site status is shown where the registry gives one.
OPN-Glendale
Arcadia, California
OPN-Los Alamitos
Los Alamitos, California
Southern California Permanente Group
Los Angeles, California
Emad Ibrahim, MD, Inc
Redlands, California
Providence Medical Foundation
Santa Rosa, California
Lutheran Medical Center - Cancer Centers of Colorado
Golden, Colorado
Eastern Connecticut Hematology & Oncology Associates
Norwich, Connecticut
Cancer Specialists of North Florida
Jacksonville, Florida
Mid Florida Hematology and Oncology Center
Orange City, Florida
Advent Health Orlando
Orlando, Florida
Napa Research
Pompano Beach, Florida
Kansas University Mediacal Center
Fairway, Kansas
Pontchartrain Cancer Center
Covington, Louisiana
Tulane University
New Orleans, Louisiana
Health Partners
Bloomington, Minnesota
Renown Health
Reno, Nevada
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire
New York City Health+HospitalsCorporation Elmhurst Hospital Center
Elmhurst, New York
Northwell Health
Queens, New York
Montefiore Medical Center
The Bronx, New York
Cleveland Clinic Mercy Hospital
Canton, Ohio
Gabrail Cancer Center
Canton, Ohio
Tricounty Hematology and Oncology Associates
Massillon, Ohio
Kaiser Permanente Northwest
Portland, Oregon
The Center for Cancer and Blood Disorders
Fort Worth, Texas
The University of Texas MD Anderson Cancer Center
Houston, Texas
Millennium Research & Clinical Development
Houston, Texas
Pro Research Tools, INC DBA Lumi Research
Kingwood, Texas
The University of Texas - Hope Cancer Center
Tyler, Texas
Innova Schar Cancer Insitute
Fairfax, Virginia
Northwest Medical Specialties
Tacoma, Washington
Klinikum Klagenfurt am Worthersee
Klagenfurt, Austria
Klinikum Klagenfurt am Wörthersee
Klagenfurt, Austria
Karl Landsteiner Institut für Lungenforschung und pneumologische Onkologie, c/o Klinik Floridsdorf Abteilung für Innere Medizin und Pneumologie
Vienna, Austria
Karl Landsteiner Institute for Lung Research and Pneumological Oncology, c/o Klinik Floridsdorf Department for Inner Medicine und Pneumology
Vienna, Austria
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, China
Anhui Chest Hospital
Hefei, Anhui, China
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
The First Affiliated Hospital of Chongqing Medical
Chongqing, Chongqing Municipality, China
Showing 40 of 129 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.